These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 34683113)

  • 41. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
    Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Circulating Tumor Cell PD-L1 Expression as Biomarker for Therapeutic Efficacy of Immune Checkpoint Inhibition in NSCLC.
    Kloten V; Lampignano R; Krahn T; Schlange T
    Cells; 2019 Aug; 8(8):. PubMed ID: 31374957
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?
    Rassy E; Mezquita L; Remon J; Besse B
    Immunotherapy; 2019 Sep; 11(13):1149-1160. PubMed ID: 31361172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
    Suresh K; Naidoo J; Lin CT; Danoff S
    Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
    Akanda ZZ; Neeson PJ; John T; Barnett S; Hanna GG; Miller A; Jennens R; Siva S
    Transl Lung Cancer Res; 2021 Jun; 10(6):2766-2778. PubMed ID: 34295676
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of immune checkpoint inhibitors in patients with advanced non-small cell lung cancer (NSCLC): a systematic literature review.
    Wagner G; Stollenwerk HK; Klerings I; Pecherstorfer M; Gartlehner G; Singer J
    Oncoimmunology; 2020 Jun; 9(1):1774314. PubMed ID: 32923134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).
    Brueckl WM; Ficker JH; Zeitler G
    BMC Cancer; 2020 Dec; 20(1):1185. PubMed ID: 33272262
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives.
    Guven DC; Sahin TK; Dizdar O; Kilickap S
    Biomark Med; 2020 Oct; 14(14):1383-1392. PubMed ID: 33064030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC.
    Chen Y; Li X; Liu G; Chen S; Xu M; Song L; Wang Y
    Front Oncol; 2020; 10():1706. PubMed ID: 33014846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Critical issues in the clinical application of liquid biopsy in non-small cell lung cancer.
    Manicone M; Poggiana C; Facchinetti A; Zamarchi R
    J Thorac Dis; 2017 Oct; 9(Suppl 13):S1346-S1358. PubMed ID: 29184673
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
    Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
    JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy.
    Passaro A; Mancuso P; Gandini S; Spitaleri G; Labanca V; Guerini-Rocco E; Barberis M; Catania C; Del Signore E; de Marinis F; Bertolini F
    Clin Transl Oncol; 2020 Apr; 22(4):603-611. PubMed ID: 31254252
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
    Doroshow DB; Sanmamed MF; Hastings K; Politi K; Rimm DL; Chen L; Melero I; Schalper KA; Herbst RS
    Clin Cancer Res; 2019 Aug; 25(15):4592-4602. PubMed ID: 30824587
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer.
    Xiong W; Zhao Y; Du H; Guo X
    Front Oncol; 2021; 11():704336. PubMed ID: 34490104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy.
    He Y; Lu M; Che J; Chu Q; Zhang P; Chen Y
    Front Oncol; 2021; 11():716844. PubMed ID: 34552872
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stereotactic radiosurgery with and without checkpoint inhibition for patients with metastatic non-small cell lung cancer to the brain: a matched cohort study.
    Shepard MJ; Xu Z; Donahue J; Eluvathingal Muttikkal TJ; Cordeiro D; Hansen L; Mohammed N; Gentzler RD; Larner J; Fadul CE; Sheehan JP
    J Neurosurg; 2020 Sep; 133(3):685-692. PubMed ID: 31349225
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.